Circio selected for oral presentation at prestigious ASGCT annual meeting

18 Mar 2026 14:45 CET

* An abstract submitted by Circio has been selected for an oral presentation
at the ASGCT annual meeting in Boston 11-15 May 2026
* ASGCT is the most important and prestigious global gene and cell therapy
conference
* The abstract publication date is 13 April 2026

Oslo, Norway, 18 March 2026 -- Circio Holding ASA (OSE: CRNA), a biotechnology
company developing novel circular RNA expression technology for gene and cell
therapy, today announces that it has been selected for an oral presentation at
the American Society of Gene and Cell Therapy annual meeting in Boston 11-15
May 2026.

The ASGCT annual meeting is the largest and most prestigious gene and cell
therapy conference globally, and widely attended by pharmaceutical and biotech
professionals, academics and life science media. Only a small number of
submitted abstracts are accepted for oral presentation.

"ASGCT is the most important event of the year in our field, and we are very
honored that the scientific committee has selected one of Circio s gene
therapy abstracts for an oral presentation," said Dr. Thomas B Hansen, CTO of
Circio. "This is an ideal opportunity to demonstrate to a broad industry
audience how our circVec technology platform significantly enhances
traditional gene and cell therapies. It is also an important arena to meet
with both existing and prospective partners to support our R&D goals and
create future business opportunities."

Circio has submitted two abstracts for ASGCT 2026, of which one has been
selected for oral presentation and one for poster presentation. Further
information about the Circio presentations and the full abstract texts will be
released on the general abstract publication date, 13 April 2026.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Neil Hunter -- Hunter PR
Phone: +44 782 125 5568
Email: neiljameshunter@gmail.com

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA
expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 40-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.

More information:
Access the news on Oslo Bors NewsWeb site